Interferon News and Research

RSS

Innate and adaptive immune responses to SARS-CoV-2 in convalescent children and adults

In a new study, researchers explored the systemic immune responses during the acute and convalescent phases of SARS-CoV-2 in children and adults with the same disease severity.

3 Feb 2022

Study describes the first three days of SARS-CoV-2 infection in an ALI model of proximal airway epithelium

Researchers evaluated the initial three days of SARS-CoV-2 infection via scRNAseq dataset in humanized in vitro model.

3 Feb 2022

Representative structures of SARS-CoV-2 and development of therapeutic agents for targeting these proteins

Researchers from China summarized the representative structures of SARS-CoV-2 proteins and discussed the development of novel therapeutic agents for targeting these proteins to treat and prevent COVID-19.

2 Feb 2022

COVID-19 vaccines induce robust cellular immune response against SARS-CoV-2 Omicron

A team of scientists from the United States has recently demonstrated that current coronavirus disease 2019 (COVID-19) vaccines induce robust spike-specific T cell responses against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

1 Feb 2022

SARS-CoV-2 protein NSP2 found to impair microRNA-induced gene silencing in human cells

In a new study, a team of researchers used co-immunoprecipitation and in vitro interaction assays to identify the molecular basis of interaction of SARS-CoV-2 non-structural protein 2 with eIF4E-homologous protein (4EHP)-GRB10-interacting glycine-tyrosine-phenylalanine domain protein 2 complex, involved in microRNA-mediated gene silencing in human cells.

1 Feb 2022

Vaccine-induced immunological memory is similar for Omicron and Delta SARS-CoV-2 variants

A new study by Norwegian researchers suggests that vaccine-induced immunological memory and the activation of recall responses in the body yields similar coverage for Omicron and Delta variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The paper is currently available on the medRxiv* preprint server while it undergoes peer review.

31 Jan 2022

Imaging microscopy shows killer T-cells targeting SARS-CoV-2 spike protein

Researchers demonstrate how cytotoxic T-lymphocytes (CTLs) with specificity for SARS-CoV-2 eliminate multiple infected targets.

30 Jan 2022

A synthesis of evidence sheds light on major immune components and mechanisms involved in COVID-19

New research highlights principal host factors that may explain the immune responses to SARS-CoV-2 and its variants in the context of infection susceptibility, disease severity, and previous immunity.

28 Jan 2022

Potential therapy candidates for patients infected with the SARS-CoV-2 Omicron variant

Researcher discusses several promising therapeutic candidates that have been proposed for the treatment of patients infected with the Omicron variant.

28 Jan 2022

Intranasal interferon-λ treatment protects mice against SARS-CoV-2 Beta and Omicron variants

Researchers investigate the possible efficacy of IFN-λ in the context of SARS-CoV-2 infection in mice.

28 Jan 2022

SARS-CoV-2 mutations and their impact on spike protein-specific T lymphocytes

New research assesses the impact of mutations in SARS-CoV-2 variants of concern (VOCs) on the T lymphocytes, specifically to the spike (S) protein of SARS-CoV-2.

27 Jan 2022

Risk of long COVID-19 predicted by immunoglobulin signature

In a new study published in the journal Nature Communications, scientists studied COVID-19 patients and found that the immunoglobulin (Ig) signature can predict the risk of PACS independently of the time point of blood sampling.

27 Jan 2022

Targeting SARS-CoV-2 M protein may help ease severity of COVID-19

A new study, published on the medRxiv preprint server, focused on the production of human CD4+ T cell lines (TCLs), reactive to either S or M protein, and analyzed if the S and M structural proteins had intrinsic differences in driving antigen-specific CD4+ T cell responses.

27 Jan 2022

T-cell apoptosis linked to poor prognosis among COVID-19 patients

Researchers assess the probability of T-cell apoptosis in patients with severe COVID-19 who were admitted to the hospital.

26 Jan 2022

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

A new study assesses SARS-CoV-2 antigen-specific cytokine responses in a cohort of SARS-CoV-2 infected individuals with varying levels of disease.

26 Jan 2022

Cross-recognition of SARS-CoV-2 vaccine-elicited T cell responses among different variants

In a new study, researchers evaluated SARS-CoV-2 vaccination-induced T cell responses cross-recognition among the early and novel SARS-CoV-2 variants.

26 Jan 2022

SARS-CoV-2 Omicron variant found to display increased resilience to antiviral type I interferon response

In a new study, scientists have compared the Omicron variant with the Delta VOC (B.1.617.2) as well as the wildtype strain (B.1), with respect to their interaction with the antiviral type 1 interferon response in infected cells.

26 Jan 2022

Understanding immune responses to SARS-CoV-2 infections in children

A study published in the journal Immunity analyzed the varied manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children.

26 Jan 2022

Cannabidiol inhibits SARS-CoV-2 replication in human cells and mice

In research recently published in the journal of Science Advances, an interdisciplinary team of researchers from the University of Chicago assessed the potential role of cannabidiol (CBD), a natural product extracted from the cannabis plant, to prevent and inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in human cells and mice.

26 Jan 2022

SARS-CoV-2 virus co-opts intrinsic cellular machinery to suppress interferon production

In a recent study posted to the bioRxiv* preprint server, researchers evaluated the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated inflammatory marker interferon (IFN) repression in hosts.

25 Jan 2022

Interferon News and Research

Innate and adaptive immune responses to SARS-CoV-2 in convalescent children and adults

Study describes the first three days of SARS-CoV-2 infection in an ALI model of proximal airway epithelium

Representative structures of SARS-CoV-2 and development of therapeutic agents for targeting these proteins

COVID-19 vaccines induce robust cellular immune response against SARS-CoV-2 Omicron

SARS-CoV-2 protein NSP2 found to impair microRNA-induced gene silencing in human cells

Vaccine-induced immunological memory is similar for Omicron and Delta SARS-CoV-2 variants

Imaging microscopy shows killer T-cells targeting SARS-CoV-2 spike protein

A synthesis of evidence sheds light on major immune components and mechanisms involved in COVID-19

Potential therapy candidates for patients infected with the SARS-CoV-2 Omicron variant

Intranasal interferon-λ treatment protects mice against SARS-CoV-2 Beta and Omicron variants

SARS-CoV-2 mutations and their impact on spike protein-specific T lymphocytes

Risk of long COVID-19 predicted by immunoglobulin signature

Targeting SARS-CoV-2 M protein may help ease severity of COVID-19

T-cell apoptosis linked to poor prognosis among COVID-19 patients

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

Cross-recognition of SARS-CoV-2 vaccine-elicited T cell responses among different variants

SARS-CoV-2 Omicron variant found to display increased resilience to antiviral type I interferon response

Understanding immune responses to SARS-CoV-2 infections in children

Cannabidiol inhibits SARS-CoV-2 replication in human cells and mice

SARS-CoV-2 virus co-opts intrinsic cellular machinery to suppress interferon production

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News